{
    "nct_id": "NCT06016270",
    "official_title": "A Phase Ib/II Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer",
    "inclusion_criteria": "* Ability to understand and sign an informed consent form\n* Male or female ≥ 18 years of age\n* Histologically or cytologically confirmed SCLC\n* R/R ES-SCLC on or after platinum-based chemotherapy for SCLC with documented disease progression\n* At least 1 measurable lesion as defined by RECIST 1.1\n* Eastern Cooperative Oncology Group Performance Score (ECOG PS) of 0 or 1\n* Life expectancy of at least 3 months\n* Adequate organ function as described in the protocol\n* For female or male patients with reproductive potential: Agree to use contraception throughout the study and at least 5 months after the last dose.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known active leptomeningeal disease (carcinomatous meningitis)\n* Known active and uncontrolled central nervous system (CNS) metastases\n* Treatment with immunotherapy, chemotherapy, targeted small molecule therapy, or any other investigational agent < 14 days prior to initiation of study treatment\n* Treatment with radiation therapy < 14 days prior to initiation of study treatment\n* Major surgery < 21 days prior to initiation of study treatment\n* Received live vaccine < 30 days prior to initiation of study treatment, including intranasal influenza vaccine\n* History of another primary malignancy with protocol-defined exceptions\n* Active or history of autoimmune disease requiring systemic treatment\n* Receiving high doses of steroids or other immunosuppressive medications\n* Active hepatitis B or C infection\n* Active or history of non-infectious pneumonitis requiring treatment with steroids\n* Active uncontrolled viral, fungal, or bacterial infection including tuberculosis\n* Pregnant or breastfeeding female patients\n* History of severe hypersensitivity reaction to a monoclonal antibody treatment\n* History of severe hypersensitivity reaction or ≥ Grade 3 adverse event (AE) to paclitaxel treatment\n* History of cerebral vascular event, unstable angina, myocardial infarction, or cardiac symptoms within 6 months prior to screening\n* QT Corrected for Fridericia's method (QTcF) > 470 ms at screening\n* Lack of resolution of any toxicity to max Grade 1 (except alopecia)\n* Active or history of any condition, therapy, or lab abnormality that may interfere with the patient participation for the full duration of the study\n* Known psychiatric or substance use disorder\n* Positive Coronavirus disease 2019 (COVID-19) test at screening",
    "miscellaneous_criteria": ""
}